Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 gene amplification in patients with breast cancer with equivocal IHC results

11 Aug 2011

Abstract excerpt

AIMS: Equivocal human epidermal growth factor receptor 2 protein (HER2) (2+) immunohistochemistry (IHC) is subject to significant interobserver variation and poses a challenge in obtaining a definitive positive or negative test result. This equivocal test result group accounts for approximately 15% of all tumours, and for optimal guidance of HER2 targeted therapy, a further analysis of quantification of gene copy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Gene expression and cancer classification
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21836036
DOI: 10.1136/jclinpath-2011-200019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 gene amplification in patients with breast cancer with equivocal IHC resultsPMID 21836036Read ↗

Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.Semantic proximity Read ↗

Discordance between Equivocal HER2 Immunohistochemistry and Fluorescence in Situ Hybridization Analysis among the Breast Carcinoma Patients in Bangladesh: A Series of 75 CasesSemantic proximity Read ↗

Gene Status in HER2 Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based MethodSemantic proximity Read ↗

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity Read ↗

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity Read ↗

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplificationSemantic proximity Read ↗

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation PracticeSemantic proximity Read ↗

Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancerSemantic proximity Read ↗

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read ↗

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ HybridizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.